Vetoquinol: Shrinking Sales Hide a Stronger Profit Engine

Vetoquinol, the French animal-health group, just delivered first-half sales that look like the company is shrinking. Revenue fell 5.4% on a reported basis in the first half of 2026, following a 2.5% drop for all of 2025. For a business that most buyers associate with the endlessly growing pet economy, a second straight year of shrinking reported revenue is jarring. Read the headline alone and the stock looks like a value trap that keeps getting cheaper.

The per-share number is not the whole story, though. Vetoquinol's reported sales are being dragged down by two things that have little to do with lost demand: exchange rates and a deliberate decision to prune low-margin products. Underneath those optics, the operating engine is moving in the opposite direction — margins are rising, the balance sheet is debt-free, and the company's biggest market is growing again. The question is whether the market, at roughly 13 times earnings, is paying you to wait for 2027 product launches or paying you to own a stagnant company.

Why the top line keeps shrinking

Vetoquinol reports in euros but sells around the world, so a strong euro mechanically shrinks its revenue when converted back. In the first quarter of 2026 alone, currency knocked about €5.2 million off sales, and the impact was concentrated in the United States and India — the two markets where a strong dollar against a weak euro and rupee hurts the most. That is not a demand problem; it is an accounting translation problem.

The second drag is deliberate. Vetoquinol has been streamlining its "Complementary" range — the lower-margin products that sit outside its core growth brands — and that pruning trims the top line even as it improves the mix. In Q1 2026 that simplification cost a further €1.7 million of sales. Strip out currency and discontinued product lines, and Q1 revenue was actually up 1.2% year over year. The reported decline of 4.3% in that quarter, and 5.4% in the half, is largely a function of these two forces, not customers walking away.

The profit story is moving the other way

What the company sells matters as much as how much. Vetoquinol has been shifting toward its "Essential" products — the strategic growth brands in companion and farm animal care — which now account for 64% of sales. Essentials grew 4.1% at constant exchange rates in 2025 and take the higher margins. That mix shift, plus pricing, lifted gross margin to 74.8% in 2025, up 280 basis points, and pushed EBITDA margin to 21.7% from 19.3% a year earlier. Net income was 10.9% of sales.

The strongest evidence of health is the one place the market is looking the least. The United States is Vetoquinol's largest market, and it re-accelerated — up 15.6% at constant exchange rates in the first quarter of 2026 after a weak stretch — driven by the same Essentials and complementary-product push. Companion animals make up about 71% of revenue, tying Vetoquinol to the fast-growing pet-spend theme that has made larger rivals like Zoetis much-loved. Adding a net cash position of roughly €206 million at the end of 2025, this is a profitable, growing-in-quality, debt-free franchise that happens to be reporting declining sales in euros.

The market has already paid for the wait

None of this is secret, which is why the stock trades where it does. At around €790 million in market value with roughly €206 million of net cash, the enterprise is worth about €580 million. That works out to roughly 13.6 times trailing earnings and around 5-6 times EBITDA — a modest multiple for a consumer-linked health franchise with a clean balance sheet and a 1.4% dividend yield. In plain terms the market is already assigning a wait-and-see price for the stagnant top line.

The honest bear case keeps this from being a slam-dunk buy. Constant-currency growth was barely positive in 2025 (+0.2%), so the underlying business is not yet genuinely accelerating — the profit gains are largely a mix-and-cost story, and the re-acceleration still rests on 2027 product launches that management itself pushes out as the reason 2026 is a "transition year." In other words, part of the cheap multiple reflects a real wait for the pipeline, not just temporary currency noise. A valuation that discounts a temporary problem is one thing; a valuation that discounts a delayed and unproven growth phase is something a buyer must make work before writing the check.

What would turn the watch into a buy

The decisive proof is narrow and falsifiable within the next few quarters. First, constant-currency sales need to turn firmly positive — not a 1.2% organic flicker, but a sustained re-acceleration driven by the US and the Essential range. Second, the margin path needs to hold: if gross margin expansion stalls once the easy mix and pricing gains are banked, the profit growth that supports the multiple loses its engine. Third, the 2027 launches have to stay on the calendar, because they are the named catalyst for the year after.

Weigh the two sides and the risk/reward tilts constructive rather than dangerous. The reported decline is real but is being driven by currency translation and voluntary product pruning, while EBITDA margin, gross margin, the US, and the balance sheet are all improving. The market has already demanded a discount for the stagnation. That makes Vetoquinol a defensible thing to watch closely — and a real purchase only once the constant-currency turn and the 2027 pipeline show they will actually deliver, rather than merely being promised. For now, the multiple absorbs a lot of the bad news, but the growth proof has not arrived yet.